These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21421116)

  • 1. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.
    de Souza JA; Olopade OI
    Semin Oncol; 2011 Apr; 38(2):263-73. PubMed ID: 21421116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of anti-estrogen treatment of breast cancer.
    Del Re M; Michelucci A; Simi P; Danesi R
    Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.
    Cronin-Fenton DP; Damkier P; Lash TL
    Future Oncol; 2014 Jan; 10(1):107-22. PubMed ID: 24328412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
    Thompson AM; Johnson A; Quinlan P; Hillman G; Fontecha M; Bray SE; Purdie CA; Jordan LB; Ferraldeschi R; Latif A; Hadfield KD; Clarke RB; Ashcroft L; Evans DG; Howell A; Nikoloff M; Lawrence J; Newman WG
    Breast Cancer Res Treat; 2011 Jan; 125(1):279-87. PubMed ID: 20809362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
    Henry NL; Rae JM; Li L; Azzouz F; Skaar TC; Desta Z; Sikora MJ; Philips S; Nguyen AT; Storniolo AM; Hayes DF; Flockhart DA; Stearns V;
    Breast Cancer Res Treat; 2009 Oct; 117(3):571-5. PubMed ID: 19153830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
    Newman WG; Hadfield KD; Latif A; Roberts SA; Shenton A; McHague C; Lalloo F; Howell S; Evans DG
    Clin Cancer Res; 2008 Sep; 14(18):5913-8. PubMed ID: 18794105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
    J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 testing in breast cancer: ready for prime time?
    Kuderer NM; Peppercorn J
    Oncology (Williston Park); 2009 Dec; 23(14):1223-32. PubMed ID: 20120834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
    Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.